GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » EV-to-FCF

Ipsen (IPSEY) EV-to-FCF : 20.02 (As of Dec. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ipsen EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ipsen's Enterprise Value is $9,245 Mil. Ipsen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $462 Mil. Therefore, Ipsen's EV-to-FCF for today is 20.02.

The historical rank and industry rank for Ipsen's EV-to-FCF or its related term are showing as below:

IPSEY' s EV-to-FCF Range Over the Past 10 Years
Min: -187.67   Med: 17.87   Max: 70.05
Current: 20.7

During the past 13 years, the highest EV-to-FCF of Ipsen was 70.05. The lowest was -187.67. And the median was 17.87.

IPSEY's EV-to-FCF is ranked better than
58% of 550 companies
in the Drug Manufacturers industry
Industry Median: 25.795 vs IPSEY: 20.70

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Ipsen's stock price is $28.65. Ipsen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.215. Therefore, Ipsen's PE Ratio (TTM) for today is 12.93.


Ipsen EV-to-FCF Historical Data

The historical data trend for Ipsen's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen EV-to-FCF Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.64 9.20 13.72 10.78 12.74

Ipsen Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 10.78 - 12.74 -

Competitive Comparison of Ipsen's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipsen's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Ipsen's EV-to-FCF falls into.



Ipsen EV-to-FCF Calculation

Ipsen's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9245.033/461.867
=20.02

Ipsen's current Enterprise Value is $9,245 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ipsen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $462 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipsen  (OTCPK:IPSEY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Ipsen's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=28.65/2.215
=12.93

Ipsen's share price for today is $28.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ipsen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.215.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Ipsen EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Ipsen's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipsen Business Description

Traded in Other Exchanges
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.